DMT / Ayahuasca

Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis.

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.

Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.

Streamlining Eligibility Assessment for Alzheimer's Disease-Modifying Therapies: Prediction of MMSE Scores Using the Digital Clock and Recall.

Beyond the toad's kiss: Mapping acute 5-MeO-DMT effects on brain connectivity across sex and dose using awake rat neuroimaging.

Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.

Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.

LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-Being: A Prospective, Naturalistic Study.

Determinants of change in disease-modifying drugs in patients with multiple sclerosis: A registry-based study.

Analysis of herpes zoster cases in multiple sclerosis patients treated with disease-modifying drugs: insights from the EudraVigilance database.

The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naïve patients with multiple sclerosis.

Effects of disease modifying therapy on cognitive proficiency in pediatric-onset multiple sclerosis (POMS).

Association of cytokine levels with treatment duration and patient family history in Egyptian multiple sclerosis patients.

Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling.

Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice.

Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Filipino Patients With Multiple Sclerosis: A Single-Center Retrospective Case Series.

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.

Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies.

5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation.

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.

Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder.

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.

The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health.

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.

Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.

Serotonergic psychedelics for depression: A comprehensive overview.

Clinical pharmacology.

Human neuroimaging: fMRI.

Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.

Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.

Psychedelics, entactogens and psychoplastogens for depression and related disorders.

Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.

The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.

Ayahuasca-inspired DMT/HAR formulation reduces brain differentiation between self and other faces.

Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression.

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.

Ayahuasca: pharmacology, safety, and therapeutic effects.

Is there a place for psychedelics in sports practice?

Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential.

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.

Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain.

The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.